Syncom Formulations Reports Record Financial Performance and Strong Market Position
Syncom Formulations (India), a small-cap pharmaceutical company, recently adjusted its evaluation following impressive financial results for the quarter ending March 2025. Key highlights include record net sales of Rs 148.88 crore and a profit after tax of Rs 17.68 crore, alongside a low debt-to-equity ratio of 0.03 times.
Syncom Formulations (India), a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an evaluation adjustment reflecting its financial performance. The company reported outstanding results for the quarter ending March 2025, showcasing significant achievements across key financial metrics. Notably, net sales reached a record high of Rs 148.88 crore, while profit before tax (PBT) less other income stood at Rs 16.35 crore. The profit after tax (PAT) also marked a high at Rs 17.68 crore, contributing to a robust earnings per share (EPS) of Rs 0.19.In addition to these financial highlights, Syncom Formulations has demonstrated a low debt-to-equity ratio of 0.03 times, indicating a solid capital structure. The company has consistently reported positive results over the last four quarters, further solidifying its market position.
On the technical front, the stock's trend has shifted to a mildly bullish stance, with indicators such as Bollinger Bands reflecting a positive outlook. This adjustment in evaluation underscores the company's strong performance metrics and favorable market conditions.
For more insights on Syncom Formulations (India) and its financial trend performance, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
